Reza Safaei, an experienced biotech executive, has joined Nordic Nanovector ASA as head of medical affairs to help the Norwegian company complete development and commercialise its antibody radionuclide conjugate for non-Hodgkin’s lymphoma. Dr Safaei was previously head of medical affairs in Europe at Seattle Genetics Inc and before that, a director of medical development at Amgen Inc.
Dr Safaei is trained in internal medicine and holds a medical degree from the University of Göttingen in Germany.
Nordic Nanovector announced the appointment on 2 August 2017.
Copyright 2017 Evernow Publishing Ltd